No clinically relevant drug-drug interactions between methadone or buprenorphine-naloxone and antiviral combination glecaprevir and pibrentasvir

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 10, 2017, Pages

  Kosloski, Matthew P ^a   Zhao, Weihan ^a   Asatryan, Armen ^a   Kort, Jens ^a   Geoffroy, Pierre ^b   Liu, Wei ^a  

^a ABBVIE INC   (United States)

^b SYNEOS HEALTH   (United States)

Author keywords

Buprenorphine; Glecaprevir; HCV; Methadone; Naloxone; Pharmacokinetics; Pibrentasvir

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; CHOLESTEROL; GLECAPREVIR; METHADONE; PIBRENTASVIR; TRIACYLGLYCEROL; ABT-493; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BUPRENORPHINE; NALOXONE; NORBUPRENORPHINE; PROTEINASE INHIBITOR; QUINOXALINE DERIVATIVE; SULFONAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASSESSMENT OF HUMANS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HUMAN; MAINTENANCE THERAPY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PUPIL; SHORT OPIATE WITHDRAWAL SCALE; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; WITHDRAWAL SYNDROME; ANALOGS AND DERIVATIVES; BLOOD; CHRONIC HEPATITIS C; CLINICAL TRIAL; DRUG EFFECT; DRUG INTERACTION; GENETICS; HEPACIVIRUS; MIDDLE AGED; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PROCEDURES; QUESTIONNAIRE; VIROLOGY; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; BUPRENORPHINE; BUPRENORPHINE, NALOXONE DRUG COMBINATION; DRUG INTERACTIONS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; METHADONE; MIDDLE AGED; NALOXONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROTEASE INHIBITORS; QUINOXALINES; SULFONAMIDES; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85029774582     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00958-17     Document Type: Article

References (26)

1. World Health Organization. July 2016. Hepatitis C fact sheet. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 18 April 2016.
2. Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GL, Lin C-W, Liu R, Lovell SS, Ng TL, Kort J, Mensa FJ. 2017. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol 67:263–271. https://doi.org/10.1016/j.jhep.2017.03.039.
3. Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. 2017. Glecaprevir and pibrentasvir for 12 weeks for HCV genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 66:389–397. https://doi.org/10.1002/hep.29081.
4. Zeuzem S, Feld JJ, Wang S, Bourliere M, Wedemeyer H, Gane EJ, Flisiak R, Chuang W-L, Flamm SL, Kwo PY, Sepulveda G, Soto-Malave R, Puoti M, Tam E, Bruck R, Fuster F, Paik SW, Felizarta F, Fu B, Ng T, Lin C-W, Mensa F. 2016. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection, abstr 253. Hepatology 64(Suppl):132A.
5. Kowdley KV, Colombo M, Zadeikis N, Mantry PS, Calinas F, Aguilar HI, de Ledinghen V, Horsmans YJ, Hu Y, Ng T, Mensa F. 2016. ENDURANCE-2: safety and efficacy of ABT-493/ABT-530 in hepatitis C virus genotype 2-infected patients without cirrhosis, a randomized, double-blind, placebo-controlled study, abstr 73. Hepatology 64(Suppl):39A.
6. Asselah T, Hezode C, Zadeikis N, Elkhashab M, Colombo M, Marinho RT, Agarwal K, Nevens F, Liu R, Ng T, Mensa F. 2016. ENDURANCE-4: efficacy and safety of ABT-493/ABT-530 treatment in patients with chronic HCV genotype 4, 5, or 6 infection, abstr 114. Hepatology 64(Suppl):63A.
7. Lorvick J, Kral AH, Seal K, Gee L, Edlin BR. 2001. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 91:46–47. https://doi.org/10.2105/AJPH.91.1.46.
8. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. 2014. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 160:293–300. https://doi.org/10.7326/M13-1133.
9. Weaver MF, Hopper JA. 2011. Treatment of opioid use and dependence. In Basow DS (ed), UpToDate. http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?26/33/27153?sourcesee_link.
10. Indivor, Inc. 2011. Suboxone® (buprenorphine and naloxone sublingual film) package insert. Indivor, Inc, Richmond, VA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022410s020s022lbl.pdf.
11. McCance-Katz EF. 2011. (R)-methadone versus racemic methadone: what is best for patient care? Addiction 106:687–688. https://doi.org/10.1111/j.1360-0443.2011.03374.x.
12. Foster DJ, Somogyi AA, White JM, Bochner F. 2004. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 57:742–755. https://doi.org/10.1111/j.1365-2125.2004.02079.x.
13. Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O. 2008. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand 52:879–889. https://doi.org/10.1111/j.1399-6576.2008.01597.x.
14. Kosloski MP, Dutta S, Pugatch D, Li H, Mensa F, Kort J, Liu W. 2016. ABT-493 and ABT-530 combination demonstrated minimal potential for CYP-mediated drug-drug interactions. J Hepatol 64(Suppl):S405.
15. Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T, Kuroiwa Y. 1998. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 26:818–821.
16. Brown SM, Holtzman M, Kim T, Kharasch ED. 2011. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3glucuronide, are biologically active. Anesthesiology 115:1251–1260. https://doi.org/10.1097/ALN.0b013e318238fea0.
17. Chang Y, Moody DE. 2009. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett 3:101–107. https://doi.org/10.2174/187231209788654117.
18. Huang P, Kehner GB, Cowan A, Liu-Chen LY. 2001. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688–695.
19. Di Marco A, D’Antoni M, Attaccalite S, Carotenuto P, Laufer R. 2005. Determination of drug glucuronidation and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay. Drug Metab Dispos 33:812–819. https://doi.org/10.1124/dmd.105.004333.
20. Kosloski MP, Dutta S, Ding B, Wang S, Kort J, Liu W, Oberoi RK. 2016. Interactions between ABT-493 plus ABT-530 combination and rilpivirine or raltegravir, abstr 453. Abstr Conf Retroviruses Opportunistic Infections, abstr 453. http://www.croiconference.org/sessions/interactions-between-abt-493-plus-abt-530-combination-and-rilpivirine-or-raltegravir.
21. Garimella T, Wang R, Luo WL, Wastall P, Kandoussi H, DeMicco M, Bruce RD, Hwang C, Bertz R, Bifano M. 2015. Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone. Antimicrob Agents Chemother 59:5503–5510. https://doi.org/10.1128/AAC.00478-15.
22. Bueno L, Fioramonti J. 1988. Action of opiates on gastrointestinal function. Baillieres Clin Gastroenterol 2:123–139. https://doi.org/10.1016/0950-3528(88)90024-3.
23. Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee S, Marinho R, DuFour J-F, Pol S, Hezode C, Gordon SC, Strasser SI, Thuluvath PJ, Liu R, Pilot-Matias T, Mensa F. 2017. High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy analysis of genotype 1 to 6 patients without cirrhosis (SAT-233). Poster presented at the International Liver Congress, 19 to 23 April 2017, Amsterdam, The Netherlands.
24. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. 1988. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 43:72–78. https://doi.org/10.1038/clpt.1988.13.
25. Gossop M. 1990. The development of a Short Opiate Withdrawal Scale (SOWS). Addict Behav 15:487–490. https://doi.org/10.1016/0306-4603(90)90036-W.
26. Franken IH, Hendriksa VM, van den Brink W. 2002. Initial validation of two opiate craving questionnaires: the obsessive compulsive drug use scale and the desires for drug questionnaire. Addict Behav 27:675–685. https://doi.org/10.1016/S0306-4603(01)00201-5.